Literature DB >> 31724864

Discovery and Optimization of Salicylic Acid-Derived Sulfonamide Inhibitors of the WD Repeat-Containing Protein 5-MYC Protein-Protein Interaction.

Jonathan D Macdonald, Selena Chacón Simon, Changho Han, Feng Wang, J Grace Shaw, Jennifer E Howes, Jiqing Sai, Joannes P Yuh, Demarco Camper, Bethany M Alicie, Joseph Alvarado, Sameer Nikhar, William Payne, Erin R Aho, Joshua A Bauer, Bin Zhao, Jason Phan, Lance R Thomas, Olivia W Rossanese, William P Tansey, Alex G Waterson1, Shaun R Stauffer1, Stephen W Fesik1.   

Abstract

The treatment of tumors driven by overexpression or amplification of MYC oncogenes remains a significant challenge in drug discovery. Here, we present a new strategy toward the inhibition of MYC via the disruption of the protein-protein interaction between MYC and its chromatin cofactor WD Repeat-Containing Protein 5. Blocking the association of these proteins is hypothesized to disrupt the localization of MYC to chromatin, thus disrupting the ability of MYC to sustain tumorigenesis. Utilizing a high-throughput screening campaign and subsequent structure-guided design, we identify small-molecule inhibitors of this interaction with potent in vitro binding affinity and report structurally related negative controls that can be used to study the effect of this disruption. Our work suggests that disruption of this protein-protein interaction may provide a path toward an effective approach for the treatment of multiple tumors and anticipate that the molecules disclosed can be used as starting points for future efforts toward compounds with improved drug-like properties.

Entities:  

Year:  2019        PMID: 31724864      PMCID: PMC6933084          DOI: 10.1021/acs.jmedchem.9b01411

Source DB:  PubMed          Journal:  J Med Chem        ISSN: 0022-2623            Impact factor:   7.446


  51 in total

Review 1.  Control of c-myc regulation in normal and neoplastic cells.

Authors:  C A Spencer; M Groudine
Journal:  Adv Cancer Res       Date:  1991       Impact factor: 6.242

2.  Synergistic blockade of mitotic exit by two chemical inhibitors of the APC/C.

Authors:  Katharine L Sackton; Nevena Dimova; Xing Zeng; Wei Tian; Mengmeng Zhang; Timothy B Sackton; Johnathan Meaders; Kathleen L Pfaff; Frederic Sigoillot; Hongtao Yu; Xuelian Luo; Randall W King
Journal:  Nature       Date:  2014-08-24       Impact factor: 49.962

3.  Selective inhibition of c-Myc/Max dimerization and DNA binding by small molecules.

Authors:  Anke Kiessling; Bianca Sperl; Angela Hollis; Dirk Eick; Thorsten Berg
Journal:  Chem Biol       Date:  2006-07

4.  SOFAST-HMQC experiments for recording two-dimensional heteronuclear correlation spectra of proteins within a few seconds.

Authors:  Paul Schanda; Eriks Kupce; Bernhard Brutscher
Journal:  J Biomol NMR       Date:  2005-12       Impact factor: 2.835

5.  Structural basis for the requirement of additional factors for MLL1 SET domain activity and recognition of epigenetic marks.

Authors:  Stacey M Southall; Poon-Sheng Wong; Zain Odho; S Mark Roe; Jon R Wilson
Journal:  Mol Cell       Date:  2009-01-30       Impact factor: 17.970

6.  Molecular shape and medicinal chemistry: a perspective.

Authors:  Anthony Nicholls; Georgia B McGaughey; Robert P Sheridan; Andrew C Good; Gregory Warren; Magali Mathieu; Steven W Muchmore; Scott P Brown; J Andrew Grant; James A Haigh; Neysa Nevins; Ajay N Jain; Brian Kelley
Journal:  J Med Chem       Date:  2010-05-27       Impact factor: 7.446

7.  Structural basis of N-Myc binding by Aurora-A and its destabilization by kinase inhibitors.

Authors:  Mark W Richards; Selena G Burgess; Evon Poon; Anne Carstensen; Martin Eilers; Louis Chesler; Richard Bayliss
Journal:  Proc Natl Acad Sci U S A       Date:  2016-11-11       Impact factor: 11.205

8.  Overview of the CCP4 suite and current developments.

Authors:  Martyn D Winn; Charles C Ballard; Kevin D Cowtan; Eleanor J Dodson; Paul Emsley; Phil R Evans; Ronan M Keegan; Eugene B Krissinel; Andrew G W Leslie; Airlie McCoy; Stuart J McNicholas; Garib N Murshudov; Navraj S Pannu; Elizabeth A Potterton; Harold R Powell; Randy J Read; Alexei Vagin; Keith S Wilson
Journal:  Acta Crystallogr D Biol Crystallogr       Date:  2011-03-18

9.  Pharmacological targeting of the Wdr5-MLL interaction in C/EBPα N-terminal leukemia.

Authors:  Florian Grebien; Masoud Vedadi; Matthäus Getlik; Cheryl H Arrowsmith; Giulio Superti-Furga; Roberto Giambruno; Amit Grover; Roberto Avellino; Anna Skucha; Sarah Vittori; Ekaterina Kuznetsova; David Smil; Dalia Barsyte-Lovejoy; Fengling Li; Gennadiy Poda; Matthieu Schapira; Hong Wu; Aiping Dong; Guillermo Senisterra; Alexey Stukalov; Kilian V M Huber; Andreas Schönegger; Richard Marcellus; Martin Bilban; Christoph Bock; Peter J Brown; Johannes Zuber; Keiryn L Bennett; Rima Al-Awar; Ruud Delwel; Claus Nerlov
Journal:  Nat Chem Biol       Date:  2015-07-13       Impact factor: 15.040

10.  Structural analysis of the KANSL1/WDR5/KANSL2 complex reveals that WDR5 is required for efficient assembly and chromatin targeting of the NSL complex.

Authors:  Jorge Dias; Nhuong Van Nguyen; Plamen Georgiev; Aline Gaub; Janine Brettschneider; Stephen Cusack; Jan Kadlec; Asifa Akhtar
Journal:  Genes Dev       Date:  2014-05-01       Impact factor: 11.361

View more
  9 in total

1.  Discovery, evaluation and mechanism study of WDR5-targeted small molecular inhibitors for neuroblastoma.

Authors:  Qi-Lei Han; Xiang-Lei Zhang; Peng-Xuan Ren; Liang-He Mei; Wei-Hong Lin; Lin Wang; Yu Cao; Kai Li; Fang Bai
Journal:  Acta Pharmacol Sin       Date:  2022-10-07       Impact factor: 7.169

2.  Discovery of a dual WDR5 and Ikaros PROTAC degrader as an anti-cancer therapeutic.

Authors:  Dongxu Li; Xufen Yu; Jithesh Kottur; Weida Gong; Zhao Zhang; Aaron J Storey; Yi-Hsuan Tsai; Hidetaka Uryu; Yudao Shen; Stephanie D Byrum; Rick D Edmondson; Samuel G Mackintosh; Ling Cai; Zhijie Liu; Aneel K Aggarwal; Alan J Tackett; Jing Liu; Jian Jin; Gang Greg Wang
Journal:  Oncogene       Date:  2022-05-07       Impact factor: 8.756

Review 3.  MYC protein interactors in gene transcription and cancer.

Authors:  Diana Resetca; Cornelia Redel; Corey Lourenco; Peter Lin; Alannah S MacDonald; Roberto Ciaccio; Tristan M G Kenney; Yong Wei; David W Andrews; Maria Sunnerhagen; Cheryl H Arrowsmith; Brian Raught; Linda Z Penn
Journal:  Nat Rev Cancer       Date:  2021-06-29       Impact factor: 60.716

4.  Discovery of WD Repeat-Containing Protein 5 (WDR5)-MYC Inhibitors Using Fragment-Based Methods and Structure-Based Design.

Authors:  Selena Chacón Simon; Feng Wang; Lance R Thomas; Jason Phan; Bin Zhao; Edward T Olejniczak; Jonathan D Macdonald; J Grace Shaw; Caden Schlund; William Payne; Joy Creighton; Shaun R Stauffer; Alex G Waterson; William P Tansey; Stephen W Fesik
Journal:  J Med Chem       Date:  2020-04-09       Impact factor: 7.446

5.  Role of WDR5 in breast cancer prognosis.

Authors:  Regina Stoeber
Journal:  EXCLI J       Date:  2019-12-16       Impact factor: 4.068

6.  Phage-Display Based Discovery and Characterization of Peptide Ligands against WDR5.

Authors:  Jiawen Cao; Tiantian Fan; Yanlian Li; Zhiyan Du; Lin Chen; Ying Wang; Xin Wang; Jingkang Shen; Xun Huang; Bing Xiong; Danyan Cao
Journal:  Molecules       Date:  2021-02-25       Impact factor: 4.411

Review 7.  Cyclobutanes in Small-Molecule Drug Candidates.

Authors:  Marnix R van der Kolk; Mathilde A C H Janssen; Floris P J T Rutjes; Daniel Blanco-Ania
Journal:  ChemMedChem       Date:  2022-03-29       Impact factor: 3.540

8.  Targeting MYC through WDR5.

Authors:  Lance R Thomas; Clare M Adams; Stephen W Fesik; Christine M Eischen; William P Tansey
Journal:  Mol Cell Oncol       Date:  2020-01-10

9.  A selective WDR5 degrader inhibits acute myeloid leukemia in patient-derived mouse models.

Authors:  Xufen Yu; Dongxu Li; Jithesh Kottur; Yudao Shen; Huen Suk Kim; Kwang-Su Park; Yi-Hsuan Tsai; Weida Gong; Jun Wang; Kyogo Suzuki; Joel Parker; Laura Herring; H Ümit Kaniskan; Ling Cai; Rinku Jain; Jing Liu; Aneel K Aggarwal; Gang Greg Wang; Jian Jin
Journal:  Sci Transl Med       Date:  2021-09-29       Impact factor: 17.956

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.